-
Sep 18, 2024 | 
jdsupra.com | Anil Shankar |Adria Warren
The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ongoing scrutiny and congressional, judicial, and industry pressures. Certain key guidance documents issued by the Health Resources and Services Administration (HRSA) were recently rejected by the courts, and additional cases are pending. Congress may ultimately decide the direction of the program.
-
Jun 5, 2024 | 
pharmaceuticalcommerce.com | Anil Shankar |Adria Warren |Jordan Smiley
June 5, 2024The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty. The 340B Drug Pricing Program continued to evolve in 2023, and further changes may be forthcoming as a result of ongoing lawsuits and regulatory action.
-
May 16, 2024 | 
mondaq.com | Anil Shankar
FL
Foley & Lardner
More
Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges.
-
May 14, 2024 | 
jdsupra.com | Anil Shankar
The Centers for Medicare & Medicaid Services (CMS) published two significant updates to its Medicaid regulations on May 10, 2024. The two Final Rules, a Medicaid Access Rule and a Medicaid Managed Care Rule, impose new requirements on states and Medicaid managed care plans that will enhance and standardize reporting, monitoring, and evaluation of Medicaid access to services. This summary highlights the key provisions of the two Final Rules that are likely to impact Medicaid reimbursement.
-
May 13, 2024 | 
natlawreview.com | Anil Shankar
Skip to main content May 13, 2024 Volume XIV, Number 134 Legal Analysis. Expertly Written. Quickly Found.
-
Apr 1, 2024 | 
mondaq.com | Adam J. Hepworth |Anil Shankar |Jordan Smiley
Leading health authorities have increasingly emphasized how
non-medical factors such as socioeconomic status, education,
employment, housing, food security, and community support have an
outsized impact on health outcomes. By some recent U.S. estimates, clinical care
accounts for only 20% of county-level variation of health outcomes
in the United States, with the social determinants of health (SDOH)
responsible for as much as 50%.
-
Mar 28, 2024 | 
jdsupra.com | Adam J. Hepworth |Anil Shankar |Jordan Smiley
Leading health authorities have increasingly emphasized how non-medical factors such as socioeconomic status, education, employment, housing, food security, and community support have an outsized impact on health outcomes. By some recent U.S. estimates, clinical care accounts for only 20% of county-level variation of health outcomes in the United States, with the social determinants of health (SDOH) responsible for as much as 50%.
-
Jul 27, 2023 | 
jdsupra.com | Stephanie Schwartz |Anil Shankar
Along with its calendar year (CY) 2024 Medicare Outpatient Prospective Payment System (OPPS) proposed rule, the Centers for Medicare & Medicaid Services (CMS) have also published the long-awaited proposal to remediate the violations that arose from Medicare’s rate cuts for 340B drugs dispensed by 340B hospitals from January 1, 2018 through September 27, 2022.
-
Jul 27, 2023 | 
lexblog.com | Anil Shankar |Stephanie Schwartz
Along with its calendar year (CY) 2024 Medicare Outpatient Prospective Payment System (OPPS) proposed rule, the Centers for Medicare & Medicaid Services (CMS) have also published the long-awaited proposal to remediate the violations that arose from Medicare’s rate cuts for 340B drugs dispensed by 340B hospitals from January 1, 2018 through September 27, 2022.
-
Apr 14, 2023 | 
natlawreview.com | Anil Shankar
Critical decisions are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program (340B Program), which provides discounts on outpatient drugs for certain health care providers, referred to as “covered entities.” The resolution of these issues will have an enormous financial impact on the health care industry, including pharmaceutical manufacturers, 340B hospitals, and federal grantees.
